Nanoporous glass (NPG) microparticles were produced by conventional melt-quenching followed by acid-alkali leaching to get material for anticancer drug carriers. NPG exhibited a positive zeta potential of 34 mV after [3-(2-aminoethylamino) propyl] trimethoxysilane treatment. The specific surface area and the total pore volume of NPG were 47.3 m2/g and 0.692 cm3/g, respectively. The 5-Fluorouracil (5FU) loading capacity of NPG was measured as 18.2 ± 0.2 mg5FU/gNPG. The drug release rate was monitored for 120 hours. To evaluate the cytotoxic effects of NPG on both MCF-7 breast cancer cells and MCF-12A, an immortalized cell line, the study employed the 2,3-bis [2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium5-carboxanilide inner salt (XTT) assay. The XTT results revealed that NPG showed a time and concentration-dependent cytotoxic effect. It is anticipated that NPG is a safe and effective material for drug delivery systems for in vitro and a promising alternative material for in vivo applications.
Ertus EB, Gulbahce-Mutlu E, Alpa S, Ozturk A. Production and biological properties of nano porous glass microparticles for anticancer drug carrier. J Appl Pharm Sci. 2024. Online First. http://doi.org/10.7324/JAPS.2024.168308
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. https://doi.org/10.3322/caac.20107 | |
2. Soule H, Vazquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973;51(5):1409-16. https://doi.org/10.1093/jnci/51.5.1409 | |
3. Nugoli M, Chuchana P, Vendrell J, Orsetti B, Ursule L, Nguyen C, et al. Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications. BMC Cancer. 2003;3(1):1-12. https://doi.org/10.1186/1471-2407-3-13 | |
4. Paine TM, Soule HD, Pauley RJ, Dawson PJ. Characterization of epithelial phenotypes in mortal and immortal human breast cells. Int J Cancer. 1992;50(3):463-73. https://doi.org/10.1002/ijc.2910500323 | |
5. Waks AG, Winer EP. Breast cancer treatment: a review. Jama. 2019;321(3):288-300. https://doi.org/10.1001/jama.2018.19323 | |
6. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219-34. https://doi.org/10.1038/nrd1984 | |
7. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16(4):215-37. https://doi.org/10.2165/00003088-198916040-00002 | |
8. Ghoshal K, Jacob ST. An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol. 1997;53(11):1569-75. https://doi.org/10.1016/S0006-2952(97)00040-3 | |
9. Dhankhar R, Vyas SP, Jain AK, Arora S, Rath G, Goyal AK. Advances in novel drug delivery strategies for breast cancer therapy. Artif Cells Blood Sub Biotechnol. 2010;38(5):230-49. https://doi.org/10.3109/10731199.2010.494578 | |
10. Arruebo M. Drug delivery from structured porous inorganic materials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012;4(1):16-30. https://doi.org/10.1002/wnan.132 | |
11. Gârea S, Mihai A, Ghebaur A, Nistor C, Sârbu A. Porous clay heterostructures: a new inorganic host for 5-fluorouracil encapsulation. Int J Pharm. 2015;491(1-2):299-309. https://doi.org/10.1016/j.ijpharm.2015.05.053 | |
12. Ouchi T, Banba T, Fujimoto M, Hamamoto S. Synthesis and antitumor activity of chitosan carrying 5-fluorouracils. Die Makromolekulare Chemie: Macromol Chem Phys. 1989;190(8):1817-25. https://doi.org/10.1002/macp.1989.021900807 | |
13. She X, Chen L, Li C, He C, He L, Kong L. Functionalization of hollow mesoporous silica nanoparticles for improved 5-FU loading. J Nanomaters. 2015;16:108-108. https://doi.org/10.1155/2015/872035 | |
14. Moodley T, Singh M. Polymeric mesoporous silica nanoparticles for enhanced delivery of 5-fluorouracil in vitro. Pharmaceutics. 2019;11(6):288. https://doi.org/10.3390/pharmaceutics11060288 | |
15. Nair L, Jagadeeshan S, Nair SA, Kumar GV. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int J Nanomed. 2011;6:1685. https://doi.org/10.2147/IJN.S20165 | |
16. Maney V, Singh M. The synergism of platinum-gold bimetallic Nanoconjugates enhances 5-fluorouracil delivery in vitro. Pharmaceutics. 2019;11(9):439. https://doi.org/10.3390/pharmaceutics11090439 | |
17. Elmer TH. Porous and reconstructed glasses. ASM International, Engineered Materials Handbook. 1991;4:427-32. | |
18. Enke D, Janowski F, Schwieger W. Porous glasses in the 21st century--a short review. Microporous Mesoporous Mater. 2003;60(1-3):19-30. https://doi.org/10.1016/S1387-1811(03)00329-9 | |
19. Nordberg ME. Properties of some Vycor-brand glasses. J Am Ceramic Soc. 1944;27(10):299-305. https://doi.org/10.1111/j.1151-2916.1944.tb14473.x | |
20. Mazilu C, Rotiu E, Ionescu L, Radu D, Dinischiotu A. Nanoporous glass in Na2O-B2O3-SiO2 oxidic system, for potential biomedical applications. J Optoelectron Adv Mater. 2007;9(7):2036-40. | |
21. Li S, Nguyen L, Xiong H, Wang M, Hu TC-C, She J-X, et al. Porous-wall hollow glass microspheres as novel potential nanocarriers for biomedical applications. Nanomed Nanotechnol Biol Med. 2010;6(1):127-36. https://doi.org/10.1016/j.nano.2009.06.004 | |
22. Ertu? EB, Vakifahmetoglu C, Öztürk A. Production and properties of phase separated porous glass. Ceram Int. 2020;46(4):4947-51. https://doi.org/10.1016/j.ceramint.2019.10.232 | |
23. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25-35. https://doi.org/10.1016/0378-5173(83)90064-9 | |
24. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-23. | |
25. Koygun G, Arslan E, Zengin G, Orlando G, Ferrante C. Comparison of anticancer activity of Dorycnium pentaphyllum extract on MCF-7 and MCF-12A cell line: correlation with invasion and adhesion. Biomolecules. 2021;11(5):671. https://doi.org/10.3390/biom11050671 | |
26. Schüth F, Sing KSW, Weitkamp J. Handbook of porous solids. Weinheim, Germany: Wiley-Vch; 2002. https://doi.org/10.1002/9783527618286 | |
27. Dau TAN, Le VMH, Pham TKH, Le VH, Cho SK, Nguyen TNU, et al. Surface functionalization of doxorubicin loaded MCM-41 mesoporous silica nanoparticles by 3-aminopropyltriethoxysilane for selective anticancer 9 effect on A549 and A549/DOX cells. J Electr Mater. 2021;50(5):2932-9. https://doi.org/10.1007/s11664-021-08813-y | |
28. Enke D, Otto K, Janowski F, Heyer W, Schwieger W, Gille W. Two-phase porous silica: Mesopores inside controlled pore glasses. Journal of materials science. 2001;36(9):2349-57. https://doi.org/10.1023/A:1017593411465 | |
29. Thommes M, Kaneko K, Neimark AV, Olivier JP, Rodriguez-Reinoso F, Rouquerol J, et al. Physisorption of gases, with special reference to the evaluation of surface area and pore size distribution (IUPAC Technical Report). Pure Appl Chem. 2015;87(9-10):1051-69. https://doi.org/10.1515/pac-2014-1117 | |
30. Šuleková M, Váhovská L, Hudák A, Žid L, Zele?ák V. A study of 5-fluorouracil desorption from mesoporous silica by RP-UHPLC. Molecules. 2019;24(7):1317. https://doi.org/10.3390/molecules24071317 | |
31. El-Kady AM, Farag MM. Bioactive glass nanoparticles as a new delivery system for sustained 5-fluorouracil release: characterization and evaluation of drug release mechanism. J Nanomater. 2015;16(1):399-399. https://doi.org/10.1155/2015/839207 | |
32. Egodawatte S, Dominguez Jr S, Larsen SC. Solvent effects in the development of a drug delivery system for 5-fluorouracil using magnetic mesoporous silica nanoparticles. Microporous Mesoporous Mater. 2017;237:108-16. https://doi.org/10.1016/j.micromeso.2016.09.024 | |
Year
Month